NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. - Wikidata - awgldk - TriplyDB

NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle.

NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle.

http://www.wikidata.org/entity/Q35044464

about

Kynurenine is an endothelium-derived relaxing factor produced during inflammation NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential Organic Nitrate Therapy, Nitrate Tolerance, and Nitrate-Induced Endothelial Dysfunction: Emphasis on Redox Biology and Oxidative Stress Extending the translational potential of targeting NO/cGMP-regulated pathways in the CVS Structure of cinaciguat (BAY 58-2667) bound to Nostoc H-NOX domain reveals insights into heme-mimetic activation of the soluble guanylyl cyclase.Insights into BAY 60-2770 Activation and S -Nitrosylation-Dependent Desensitization of Soluble Guanylyl Cyclase via Crystal Structures of Homologous Nostoc H-NOX Domain Complexes Heme-dependent and independent soluble guanylate cyclase activators and vasodilation.Fluorescence dequenching makes haem-free soluble guanylate cyclase detectable in living cells Chronic Activation of Heme Free Guanylate Cyclase Leads to Renal Protection in Dahl Salt-Sensitive Rats.The Concise Guide to PHARMACOLOGY 2013/14: enzymes.Cardiac myosin activation: a potential therapeutic approach for systolic heart failure.PDE-5 inhibition impedes TSP-1 expression, TGF-beta activation and matrix accumulation in experimental glomerulonephritis.Vasodilator responses to acetylcholine are not mediated by the activation of soluble guanylate cyclase or TRPV4 channels in the rat.Is Nostoc H-NOX a NO sensor or redox switch?Targeting soluble guanylate cyclase for the treatment of pulmonary hypertension.Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase stimulator, BAY 41-8543, are modulated by nitric oxide.cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action.Estrogen-induced apoptosis of breast epithelial cells is blocked by NO/cGMP and mediated by extranuclear estrogen receptors.Development of Therapeutics That Induce Mitochondrial Biogenesis for the Treatment of Acute and Chronic Degenerative Diseases.Soluble guanylate cyclase as a novel treatment target for osteoporosis.Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase activator, BAY 60-2770, are not dependent on endogenous nitric oxide or reduced heme.Pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in healthy male volunteers.The soluble guanylate cyclase activator BAY 58-2667 protects against morbidity and mortality in endotoxic shock by recoupling organ systems Involvement of beta 3-adrenergic receptor activation via cyclic GMP- but not NO-dependent mechanisms in human corpus cavernosum function.A Rho-kinase inhibitor, soluble guanylate cyclase activator and nitric oxide-releasing PDE5 inhibitor: novel approaches to erectile dysfunction.Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease.Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.sGC{alpha}1 mediates the negative inotropic effects of NO in cardiac myocytes independent of changes in calcium handling Gas what: NO is not the only answer to sexual function.The soluble guanylate cyclase stimulator BAY 41-2272 inhibits vascular smooth muscle growth through the cAMP-dependent protein kinase and cGMP-dependent protein kinase pathways.Cinaciguat, a soluble guanylate cyclase activator, augments cGMP after oxidative stress and causes pulmonary vasodilation in neonatal pulmonary hypertension.Phosphodiesterases Regulate BAY 41-2272-Induced VASP Phosphorylation in Vascular Smooth Muscle Cells.Cinaciguat, a novel activator of soluble guanylate cyclase, protects against ischemia/reperfusion injury: role of hydrogen sulfide.Reduced vascular responses to soluble guanylyl cyclase but increased sensitivity to sildenafil in female rats with type 2 diabetes.Wen-Xin Decoction ameliorates vascular endothelium dysfunction via the PI3K/AKT/eNOS pathway in experimental atherosclerosis in rats.Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilation.The soluble guanylyl cyclase activator bay 58-2667 selectively limits cardiomyocyte hypertrophy.Heme-assisted S-nitrosation desensitizes ferric soluble guanylate cyclase to nitric oxide Pathophysiology of hypertension in the absence of nitric oxide/cyclic GMP signaling.

P2860

Q24630488-FC244DCD-088A-4CF8-A2FF-5850DEB0D18B Q24656131-00802BD0-06D9-4DE7-82AE-5657FE3777DB Q26799354-E2239A75-7A0A-4E2D-A97D-D7995431B001 Q27021649-56E5690C-E1BD-4771-9A59-E95BA3EEA16D Q27661554-C4897BD4-E040-43C1-994D-07A5D12CBC70 Q27677544-F94AFA07-B7C6-41F0-996A-291A683D43D7 Q27692662-AF5B059F-CD2E-42C2-96F2-F26820FF638F Q28741339-CDD4B86F-BCC2-4559-9405-DADE3C67D259 Q30315850-2516C987-8FB6-4F47-B50A-A2735D5B93FC Q30486745-C6EDE2D3-C28D-4BBE-B57E-A98FCD165C56 Q30583292-F2172BE7-C021-4930-BE83-0225D061D754 Q33348441-AF3FD292-0004-4563-9B9A-746054C1B884 Q33701956-C0D56B9F-F1DF-4CE3-8E43-202B30ED2A09 Q34039950-FBC31A59-7899-4413-82B3-DD082B4C1E73 Q34179857-C9F36E91-B45A-41B3-955C-83273D13B298 Q34212268-BFB764BE-FC97-4B67-AFE2-9151BD8C70FF Q34244951-2EAB86D8-A2F9-4249-B38E-4EE9B8D89862 Q34392623-EC6CC532-C3FB-4DA7-A73F-6B2E046E0889 Q34538482-EA079319-10E3-4FD8-B54D-58A09528C7EA Q34551704-4A92A08A-82D6-4790-8B02-43343A716A06 Q34720361-A4B1FCBF-2770-44D4-BE04-49403BF4C106 Q34823612-7BEE9D16-B4A5-4952-8C3A-5E5EDF283A71 Q34981386-DB36053C-6C0A-408B-902D-BD983623A71D Q34983511-5DEF0D7A-75C0-4202-8BC4-97833E898BD0 Q35001011-120EB539-E8D8-45F0-BCED-96A3AD5F8EB7 Q35009484-31FAC308-07A3-4D69-B673-93BEFA48AB67 Q35010064-6740EBEB-DDEC-4D66-916D-03323AB00B4C Q35075847-37D8A388-EE6E-43F5-9F23-13ED7DD42E5C Q35087054-99C741A2-B04C-48BC-926F-AA9AF0CC5BFD Q35204833-CF2032D3-0D6E-489C-9ADA-94043A8EFFBE Q35429867-858DD2F4-72F6-45A8-B9A4-9B7D5BC11984 Q35543584-7CB7E040-EFE6-45CE-9A69-99D723A8BD45 Q35740400-980971CE-6C20-4029-967A-DCB40C318BD4 Q35850118-F7822F55-66D4-4073-93EE-F053745B9A04 Q35859307-55495A1F-0E64-4C11-8BA9-B6DA42CE1DED Q35902454-D624B298-863D-4605-929A-B0ED0A990191 Q36330594-4E0946DD-F6FC-4669-B593-FA25E4E98BF4 Q36380981-76104CFB-8026-4CA8-AA52-2ADD6CE4A914 Q36466804-DD6BFBCF-1F2A-41A9-A311-173BC449BC4F Q36532454-494F56F2-35AD-411E-83FF-7983241900B6

P2860

NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle.

http://www.wikidata.org/entity/Q35044464

description

2002 nî lūn-bûn

@nan

2002 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

NO- and haem-independent activ ...... new pharmacological principle.

@en

type

label

NO- and haem-independent activ ...... new pharmacological principle.

@en

prefLabel

NO- and haem-independent activ ...... new pharmacological principle.

@en

P1433

Q35044464-3A88B4BE-57FE-4ABD-B23D-C2A4DB6BC382

P1476

Q35044464-C68A3D02-EEBB-4C84-9DE2-B7C9AF82A168

P2093

Q35044464-09C7FF02-A28C-4E55-A5F6-9593E8780F83

Q35044464-37EC8466-D4B8-47C9-9EFA-9D0DBA85AADF

Q35044464-41995C73-0640-4867-A4E8-4289BA0E04AC

Q35044464-65D7F3A0-057A-4D1A-8A11-817188C96B0C

Q35044464-6F4EE4DC-885E-4C08-B57D-47AEE9326AF5

Q35044464-72C99CAB-9639-4B8A-9215-1DE31C757E70

Q35044464-A3CF1FDC-5451-41E4-86BC-6B75605535A4

Q35044464-A60CAE3B-9E81-4329-AD8C-E0785D7C12E0

Q35044464-B3EDA405-F9F2-4F98-8681-B2D8CD02665A

Q35044464-C7C1B1D7-7758-411E-838F-4E4C5D7323E6

P2860

Q35044464-04F9BA38-3EEA-495B-A30E-8C7420198A93

Q35044464-09FF195F-40F1-4E57-8B2C-078D4BD288F0

Q35044464-0BA16FAD-AF1F-43B0-B894-50947EC64239

Q35044464-1E291E23-3376-44F6-A9BB-4E603749B4E2

Q35044464-3D159A80-43BD-4F28-AD37-6DBE335A79BB

Q35044464-495B82D7-610B-4AE4-9D92-C1D808485CEA

Q35044464-4DB5C864-702C-4892-931C-F9FC14DCFF8C

Q35044464-57C3BE91-B3AA-4892-82ED-0126C7465380

Q35044464-5AD03A84-E7BF-49DA-B571-F220C759A759

Q35044464-75E96129-5D5B-4216-AA22-544C88C99B57

P304

Q35044464-C96D300C-0858-423C-9704-0430023A1746

P31

Q35044464-2B31A798-76A5-419B-8EE9-75C766581A36

P356

Q35044464-15AA3BBA-ECC6-4C3F-9D94-0C6B35D4CF98

P407

Q35044464-732E079F-470C-4799-B3FB-B98A8DEFF243

P433

Q35044464-8C3C1F96-73E8-4F43-8551-6C39EC8A1DC4

P478

Q35044464-08C0A698-9C6D-4D40-9631-4273ECC6E52A

P50

Q35044464-BEBB1232-9074-4B41-8B7A-EA484FBD087A

P577

Q35044464-ADF5C021-45B3-40A7-8595-28D3D5535A50

P5875

Q35044464-0FCDEEA0-25F3-4475-AE8E-C7CD5BE0C2F3

P698

Q35044464-478F69B3-1898-4C28-9D55-3CE375251CB7

P932

Q35044464-09858D8F-CCA4-4EAE-AF3F-8DEF00FEB91D

P356

P1433

British Journal of Pharmacology

P1476

NO- and haem-independent activ ...... new pharmacological principle.

@en

P2093

Cristina Alonso-Alija

http://www.w3.org/2001/XMLSchema#string

Elisabeth Perzborn

http://www.w3.org/2001/XMLSchema#string

Elke Stahl

http://www.w3.org/2001/XMLSchema#string

Frank Wunder

http://www.w3.org/2001/XMLSchema#string

Heiner Apeler

http://www.w3.org/2001/XMLSchema#string

Henning Schröder

http://www.w3.org/2001/XMLSchema#string

Klaus Dembowsky

http://www.w3.org/2001/XMLSchema#string

Markus Heil

http://www.w3.org/2001/XMLSchema#string

Matthias Schramm

http://www.w3.org/2001/XMLSchema#string

Michael Haerter

http://www.w3.org/2001/XMLSchema#string

P2860

Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications

High resolution two-dimensional electrophoresis of proteins

NO-independent regulatory site of direct sGC stimulators like YC-1 and BAY 41-2272

Nitric oxide: physiology, pathophysiology, and pharmacology

Crystal structure of the catalytic domains of adenylyl cyclase in a complex with Gsalpha.GTPgammaS

Sensitizing soluble guanylyl cyclase to become a highly CO-sensitive enzyme

NO-independent regulatory site on soluble guanylate cyclase.

Tolerance to organic nitrates: evidence, mechanisms, clinical relevance, and strategies for prevention.

YC-1 activation of human soluble guanylyl cyclase has both heme-dependent and heme-independent components

Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies

P304

773-783

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJP.0704778

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

136

http://www.w3.org/2001/XMLSchema#string

P50

Johannes-Peter Stasch

P577

2002-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11288458

http://www.w3.org/2001/XMLSchema#string

P698

12086987

http://www.w3.org/2001/XMLSchema#string

P932

1573403

http://www.w3.org/2001/XMLSchema#string